Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Liabilities and Shareholders Equity (2021 - 2025)

Historic Liabilities and Shareholders Equity for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to $40.9 million.

  • Verrica Pharmaceuticals' Liabilities and Shareholders Equity rose 2420.2% to $40.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.3 million, marking a year-over-year decrease of 2427.67%. This contributed to the annual value of $54.1 million for FY2024, which is 3365.69% down from last year.
  • Verrica Pharmaceuticals' Liabilities and Shareholders Equity amounted to $40.9 million in Q3 2025, which was up 2420.2% from $39.1 million recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $108.1 million during Q1 2021, and its lowest value of $32.9 million during Q3 2024.
  • Over the past 5 years, Verrica Pharmaceuticals' median Liabilities and Shareholders Equity value was $63.4 million (recorded in 2022), while the average stood at $65.4 million.
  • Per our database at Business Quant, Verrica Pharmaceuticals' Liabilities and Shareholders Equity soared by 9766.82% in 2023 and then plummeted by 6610.64% in 2024.
  • Quarter analysis of 5 years shows Verrica Pharmaceuticals' Liabilities and Shareholders Equity stood at $80.1 million in 2021, then tumbled by 44.19% to $44.7 million in 2022, then surged by 82.46% to $81.6 million in 2023, then plummeted by 33.66% to $54.1 million in 2024, then fell by 24.45% to $40.9 million in 2025.
  • Its Liabilities and Shareholders Equity was $40.9 million in Q3 2025, compared to $39.1 million in Q2 2025 and $42.2 million in Q1 2025.